Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROCEPT BioRobotics (PRCT) Other Accumulated Expenses (2020 - 2026)

PROCEPT BioRobotics has reported Other Accumulated Expenses over the past 7 years, most recently at $10.2 million for Q1 2026.

  • Quarterly Other Accumulated Expenses rose 20.88% to $10.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $10.2 million through Mar 2026, up 20.88% year-over-year, with the annual reading at $10.1 million for FY2025, 24.53% up from the prior year.
  • Other Accumulated Expenses was $10.2 million for Q1 2026 at PROCEPT BioRobotics, up from $10.1 million in the prior quarter.
  • Over five years, Other Accumulated Expenses peaked at $10.2 million in Q1 2026 and troughed at $4.0 million in Q1 2022.
  • The 5-year median for Other Accumulated Expenses is $7.8 million (2023), against an average of $7.7 million.
  • Year-over-year, Other Accumulated Expenses skyrocketed 109.21% in 2022 and then decreased 15.4% in 2023.
  • A 5-year view of Other Accumulated Expenses shows it stood at $7.5 million in 2022, then decreased by 15.4% to $6.3 million in 2023, then increased by 28.03% to $8.1 million in 2024, then rose by 24.53% to $10.1 million in 2025, then increased by 1.75% to $10.2 million in 2026.
  • Per Business Quant, the three most recent readings for PRCT's Other Accumulated Expenses are $10.2 million (Q1 2026), $10.1 million (Q4 2025), and $8.2 million (Q3 2025).